CAMA-1: Human Breast Cancer Cell Line (ATCC HT-21)

SK 926

CAMA-1: Human Breast Cancer Cell Line (ATCC HT-21)

SK 926


CAMA-1 is a luminal-type human breast cancer cell line that displays rounded morphology in adherent tissue culture. These cells are considered Her2-negative and estrogen-receptor/progesterone-receptor (ER/PR)-positive. They are responsive to estrogen and sensitive to growth inhibition by tamoxifen. The CAMA-1 cells have an in-frame mutation in the E-cadherin gene, resulting in a truncated, non-functional protein. In addition, they have oncogenic mutations in PTEN and p53 and amplification of the cyclin D1 gene.


This cell line was established in 1975 from the pleural effusion of a 51-year-old Caucasian female with malignant adenocarcinoma of the breast.


Jorgen Fogh, PhD, formerly at Sloan Kettering Institute, Memorial Sloan Kettering

Key References

  • Fogh J et al. (1977) Absence of HeLa cell contamination in 169 cell lines derived from human tumors. Journal of the National Cancer Institute 58: 209-214 (PubMed ID: 833871)
  • Ji H et al. (1994) Absence of transforming growth factor-beta responsiveness in the tamoxifen growth-inhibited human breast cancer cell line CAMA-1. Journal of Cellular Biochemistry 54: 332-342 (PubMed ID: 8200913)
  • van Horssen R et al. (2012) E-cadherin promotor methylation and mutation are inversely related to motility capacity of breast cancer cells. Breast Cancer Research and Treatment 136: 365-377 (PubMed ID: 23053649)

Licensing Information

This cell line may be licensed nonexclusively for research or commercial purposes.

  • Express License:  For internal research purposes by a for-profit entity:  1) Fill out MSK’s ATCC Express License, see here for links to the online fillable ATCC Express License, as well as a PDF version.  2) After execution by MSK, you will receive a signed copy, and can then place your order with ATCC. For detailed guidance on how to fill out this webform, see here. Please note:  In order to streamline and expedite the licensing of select MSK cell lines, the terms of this non-exclusive license are non-negotiable. This license is only available for select cell lines, including this one. Once this license has been executed by MSK, you will receive a signed copy and payment instructions; all payments up to $10,000 must be made by credit card.
  • Commercial License: Contact MSK’s Tangible Materials team at [email protected].

For non-licensing requests from academic-research institutions: Contact Frances Weis-Garcia, PhD, Associate Laboratory Member/Head, Antibody & Bioresource Core Facility, MSK, 646-888-2354, [email protected]

Stage of Development

Ready to use